Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Akero Therapeutics stock target cut by Canaccord, retains buy rating

EditorAhmed Abdulazez Abdulkadir
Published 13/05/2024, 12:16
AKRO
-

On Monday, Akero Therapeutics Inc . (NASDAQ:AKRO) saw its 12-month price target adjusted by Canaccord Genuity, with the new target set at $56.00, down from the previous $59.00. Despite this change, the firm has maintained a Buy rating on the biotechnology company's stock.

The adjustment in the price target comes after Canaccord Genuity revised its financial model for Akero Therapeutics, taking into account the company's most recent financial results. The decrease in the price target is primarily due to updated projections for the fiscal year 2024 operating expenses.

Canaccord Genuity has increased its estimated Research and Development (R&D) expenses for the fiscal year 2024 from $179 million to $212 million. Additionally, the firm has raised its estimate for Selling, General, and Administrative (SG&A) expenses from $37 million to $40 million. These revisions are based on Akero Therapeutics' ongoing and upcoming involvement in three large-scale Phase III clinical studies throughout the year.

The company's increased financial commitment to these studies is reflected in the higher projected operating costs. The Buy rating suggests that Canaccord Genuity remains optimistic about Akero Therapeutics' potential despite the higher anticipated expenses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.